SentinelOne is making a major push this year around AI-powered SIEM, as well as cloud and data security, Channel Chief Brian ...
Boehringer Ingelheim announced today that the FIBRONEERâ„¢-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.
Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...
4h
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
In today's digital landscape, data processing can occur either at centralized locations like data centers and on-premise ...
Sycomp A Technology Company, Inc., announced today that CRN®, a brand of The Channel Company, has named Sycomp to its Managed ...
Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...
SYMPHONY Communication Public Company Limited (SYMC), a prominent telecommunication network service provider, has announced a ...
Europe logistic projects since the Chinese Belt Road. Ukraine and Italy will play a part in the India-Middle ...
CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback